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Genetic and genomic methods are now integral to our study of 
the biology and epidemiology of disease and can offer insight 
into diseases that develop in the body and how these spread in 
communities. Genomic research methods can also assist in the 
identification of new targets for drug and vaccine development and 
can reveal valuable information regarding drug effectiveness and 
potential drug toxicity in particular persons or groups. 
There are several ways in which genomic research can be of 
relevance to patients in clinics, in addition to providing high-level 
information about disease at the population level. For instance, 
researchers are increasingly exploring how personal genomic tests 
could be used to better attune the care that a person receives. This 
could be done by predicting the drug dose that may be most effective 
for that person by identifying specific individuals more at risk of 
spreading viruses[1] or by predicting which individuals are more at 
risk of developing particular conditions and should therefore be 
subjected to more regular screening.
Against this background, there are a number of important ethical 
considerations that need to inform both the conduct of genomic 
research, but also the gradual introduction or expansion of genomic 
medicine in South African (SA) clinics. We describe a selection of 
these in this article. A more detailed description of some of these 
challenges can be found in a recent consensus study report by the 
Academy of Science of South Africa (ASSaf) on the ethical, legal and 
social implications of genetics and genomics in SA.[2]
Informed consent
Consent is a key pillar of health research, which is always required in 
SA unless an ethics committee has waived the need to obtain consent 
in exceptional circumstances. Valid consent is consent voluntarily 
given by a competent person on the basis of sufficient information. 
The test case for the latter is that the consent process should provide 
information that a reasonable person would possibly want to know – 
which is different from requiring ‘all’ information. 
A particular challenge in the context of genetic and genomic 
research is that samples and data can be stored and re-used for 
multiple projects over long periods of time, including projects that 
are far removed from the original purpose for which samples and 
data were collected. The possibility for the broad future re-use of 
samples and data is in conflict with the traditionally specific nature 
of consent, where data and samples were collected for a specific 
purpose.
One response to this matter is the introduction of a so-called ‘broad 
consent’ model that allows for future re-use of samples and data for 
a number of specific purposes. Broad consent is described as being 
a permissible consent model in the SA National Ethics in Health 
Research guidelines.[3] It is different from ‘blanket consent’; broad 
consent is subject to a number of clearly defined process and content 
restrictions.[4] These include limitations on the kinds of purposes the 
samples and data will be used for, which can be set to accommodate 
identified concerns, e.g. from a patient group or community. An 
example could be that the consent form for samples collected for a 
schizophrenia genomic study indicates that samples and data will 
also be used for other future psychiatric genomic research. Another 
important restriction that should accompany the use of broad consent 
is that it be used only when researchers have already described how 
and where samples and data will be stored, who will have access to 
these resources, and who will make decisions. Details regarding this 
governance framework should be included in the consent process. 
Community engagement
Genomics research has seen an evolving recognition to focus on the 
protection of individual research participants and on that of their 
communities. One reason why this is considered important is that 
community engagement recognises more communitarian values 
traditionally strong in African societies.[5] Community engagement 
requires, for example, including communities in discussions on the 
ethics of genomic research, developing benefit-sharing arrange-
ments and acknowledging the contributions of study populations. 
Community engagement is based on principles of solidarity, recipro-
city, inclusiveness and mutual respect, which are characteristic of 
communitarian settings. 
A range of approaches have been developed to foster community 
engagement for genomic research.[6] For example, Stellenbosch 
University’s Centre for Medical Ethics and Law has developed a range 
of tools to support community engagement around biobanking. This 
includes an educational video that is freely available for download and 
use (https://www.sun.ac.za/english/faculty/healthsciences/cmel/elsi). 
The SA National Bioinformatics Institute is also piloting a bilingual 
(English-Xhosa and English-Afrikaans) book that uses a combination 
of text, colourful illustrations and recorded audio (‘speaking book’) to 
communicate concepts in genomics, informed consent, biobanking 
and medical research (www.uwc.ac.za/Faculties/NS/News/Pages/
SANBI-pilots-it’s-biobank-bilingual-speaking-books.aspx). Another 
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helpful resource was created by researchers in Botswana, who 
developed a series of 4 comic books that together introduce 
key concepts in genomic research (http://botswanabaylor.org/
genome_adventures.html). These resources are freely available and 
could be adapted to better fit the SA research context. 
The possibility for genetic 
discrimination and stigmatisation
A recurring fear in the context of genetic and genomic research 
relates to the possibility that it could cause or increase stigma 
for patient or population groups. Specifically, the concern is that 
genetic information could be used to ‘taint’ or ‘mark’ members of 
those groups.[7] A recent SA example[8] suggests that, as a minimum, 
genomic research could reveal information about a population group 
that was considered private by members of that group, translating into 
a potential for reputational harm. While it is important to consider 
that the process of stigmatisation involves more than just ‘marking’ 
a group,[9] genomic researchers need to be cognisant of the risk of 
their research and the presentation of the results being perceived as 
offensive or stigmatising by participants and communities. 
Feedback of findings 
Genomic research has the potential to identify a select number 
of individual findings that could be relevant to the health of 
the individual.[10] Lists of mutations that should be considered 
for feedback are available in the USA (https://www.snpedia.com/
index.php/ACMG_recommendations_for_reporting_of_incidental_
findings_in_clinical_exome_and_genome_sequencing) and in the UK 
(https://www.genomicsengland.co.uk/information-for-participants/
findings/). Overall, the consensus seems to be that individual genetic 
findings that are: (i) medically actionable or have clinical utility; 
(ii) robustly associated with disease causation; and (iii) unlikely 
to have been diagnosed without the genetic finding, should be fed 
back to participants.[11] Ideally, there should be some indication that 
participants would want to receive findings, e.g. because they were 
asked during the consent process. 
A particular challenge in determining which findings should be 
fed back in SA genomic research, however, relates to the relative 
scarcity of population-level genomic data that can help to predict 
whether detected variants are possibly benign or pathogenic. A second 
challenge relates to possibilities for diagnostic validation of research 
results in accredited National Health Laboratory Service (NHLS) 
laboratories in SA. Such validation will possibly be costly and could 
increase the burden on these genetic diagnostic laboratories. If there is 
no possibility to validate the research results, the question is whether 
it is appropriate to return unvalidated results. The question is whether, 
if there is no possibility to validate the research result, it is appropriate 
to return unvalidated research results. In light of these uncertainties, 
the current preference seems to be to inform participants that no 
individual genetic research results will be fed back. 
Genomic research for the benefit of 
South Africans
Debates on the ethics of genomic research in Africa are strongly 
premised on the notion of equity. This comes to the fore, for instance, 
in terms of the scientific imperative for extending genomic studies 
to African populations to ensure that genomic research is fair and 
inclusive.[12] There is also the representation of SA researchers in 
population genomic studies carried out in this country. It is almost 
impossible to discuss ethical issues in genomics without taking into 
consideration the differences in resources and capacity between SA 
researchers and their collaborators in high-income countries, as 
well as the historical narrative of exploitation of African scientists 
in international health research collaborations. Suggestions have 
been made to minimise exploitation of African researchers and to 
achieve equitable research collaborations,[13] some of which include: 
leadership of genomic projects by local researchers; capacity building; 
giving voice to local researchers in decision-making within genomic 
collaborations; and allowing local researchers to define the research 
agenda. An important component of ensuring fairness is also the 
equitable sharing of research resources, which may include data, 
biological samples, intellectual property and financial resources. 
Equally important is the need to ensure that collaborations 
between SA research institutions are equitable. Otherwise, concerns 
of exploitation, which have plagued global health research, may be 
replicated in in-country collaborations. Developing models and 
resources for equitable genomic collaborations for in-country and 
global research is important. The Council on Health Research 
for Development provides a number of resources and guidelines 
that could help in navigating some of the tensions in research 
collaborations.[14] 
The importance of genomics in SA populations will be more visible 
if genomic medicine is available in clinics and if it is accessible and 
affordable. This will require that healthcare practitioners receive 
specialised training in genetics and genetic counselling, as well 
as local investment in genomic medicine. But first and foremost, 
genomic research in SA should be tailored to the health needs of 
the SA population. It will therefore be important to identify national 
priorities for genomic research. 
Regulation of genomic research in 
South Africa
The law governing genomic research is contained in several pieces 
of legislation, including the SA Constitution, which grants a right to 
privacy, the National Health Act, 2008 and the Protection of Personal 
Information Act (PoPIA), 2013, once it has been enacted.[2] Importantly, 
SA legislation comprehensively protects against discrimination (and 
stigmatisation as a form of discrimination), including discrimina-
tion on the grounds of one’s genetic material. Regulations regarding 
sample export are in place and need to be followed by researchers 
conducting genomic research that requires export, including seeking 
an export permit from the National Department of Health.[15] An 
important question relating to the conduct of genomic research is 
whether and how the use of broad consent will be allowed once the 
PoPIA becomes effective, which is expected in 2020. There is a pos-
sibility that rigorous interpretation of the PoPIA would prevent the 
use of genetic samples and data for research projects not specifically 
described in consent forms used in their collection and would thus 
effectively dampen genomic research.[16]
Conclusions 
Genomic research raises a range of ethical challenges that need to 
be considered in its design and execution. Some of these relate to 
how samples and data are collected and include considerations of 
consent and community engagement. Others more broadly relate 
to the research process, and include considerations of justice and 
fairness, including ensuring that research is of benefit to the SA 
population. 
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